Atsetylsalytsylovaya acid | Thrombo ACC tablets coated. 50 mg 100 pcs.
Special Price
$15.52
Regular Price
$23.00
In stock
SKU
BID472539
Release form
Enteric coated tablets.
Enteric coated tablets.
Release form
Enteric coated tablets.
Packing
100 pcs.
Pharmacological action
Thrombo Ass - NSAIDs, antiplatelet agent.
Reduces blood coagulation due to a decrease in platelet aggregation by suppressing the synthesis of thromboxane A2 in them.
The use of thrombo ACC, starting with a dose of 50 mg, leads to a long-term decrease of serum thromboxane A2 and its metabolites by 90-95%.
It also has anti-inflammatory, analgesic and antipyretic effects.
The tablets of the drug are coated with a film of enteric coat resistant to the action of gastric juice, which reduces the risk of side effects from the stomach.
Indications
- prevention of acute myocardial infarction in the presence of risk factors (such as diabetes mellitus, hyperlipidemia, hypertension, obesity, smoking, elderly)
- secondary prevention of myocardial infarction
- unstable angina pectoris (
- angina pectoris in patients with transient cerebrovascular diseases)
- prevention of transient cerebrovascular disorders
- prevention of thromboembolism after surgery and invasive vascular interventions (such ak aorto-coronary bypass, carotid endarterectomy, arterio-venous bypass, angioplasty, carotid arteries)
- prevention of deep vein thrombosis and pulmonary artery and its branches (e.g., with prolonged immobilization as a result of serious surgery).
Contraindications
- erosive and ulcerative lesions of the gastrointestinal tract, gastrointestinal bleeding
- aspirin asthma (bronchial asthma induced by taking salicylates and NSAIDs)
- aspirin triad (a combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to acetylsalicylic acid)
- hemorrhagic diathesis
- combined use with methotrexate at a dose of 15 mg or more per week
- I and III trimesters of pregnancy
- lactation (breastfeeding and nursing) 18 years of
- hypersensitivity to acetylsalicylic acid, to excipients of the drug Thrombo ACC and other NSAIDs.
It is prescribed with caution in case of gout, hyperuricemia, gastrointestinal ulcer or history of gastrointestinal bleeding, renal and hepatic insufficiency, bronchial asthma, chronic respiratory diseases, hay fever, nasal polyposis, allergic reactions to medications, history with simultaneous use with methotrexate at a dose of 15 mg or less per week.
Use during pregnancy and lactation
The use of high doses of salicylates in the first 3 months of pregnancy is associated with an increased incidence of fetal developmental defects (split palate, heart defects). In the second trimester of pregnancy, salicylates can only be prescribed with a strict assessment of risk and benefit. The appointment of ASA in the last trimester is contraindicated.
Salicylates and their metabolites in small doses pass into breast milk. Long-term use of salicylates is a reason for stopping breastfeeding. A random intake of salicylates during lactation is not accompanied by the development of adverse reactions in the child and does not require cessation of breastfeeding.
Special instructions
ASA can cause bronchospasm, as well as cause asthma attacks and other hypersensitivity reactions. Risk factors are a history of asthma, hay fever, nasal polyposis, chronic respiratory diseases, as well as allergic reactions to other drugs (itching, urticaria).
ASA can cause bleeding of varying severity during and after surgery.
The combination of ASA with anticoagulants, thrombolytics, antiplatelet agents is associated with an increased risk of bleeding.
ASA in low doses can trigger gout in susceptible individuals with decreased uric acid excretion.
The combination of ASA with methotrexate is accompanied by an increased incidence of side effects from the hematopoietic system.
High doses of ASA have a hypoglycemic effect, which must be considered when prescribing it to patients with diabetes mellitus receiving hypoglycemic drugs.
When combined with GCS, it should be remembered that during treatment, the level of salicylates in the blood is reduced, and after the abolition of GCS, an overdose of salicylates is possible.
The combination of ASA with ibuprofen is not recommended, since the latter worsens the beneficial effect of ASA on life expectancy.
When combined with ASA and alcohol, the risk of damage to the gastrointestinal mucosa and prolonged bleeding time is increased.
Composition
1 tablet: - acetylsalicylic acid 50 mg.
Excipients:
lactose, microcrystalline cellulose,
silicon dioxide colloidal,
potato starch,
talcum powder,
triacetin,
silicone anti-foaming agent SE2,
is emulsified with L30D (methacrylic acid and ethacrylate copolymer).
Dosage and Administration
Thrombo ACC tablets should be taken orally without chewing before meals with a small amount of liquid.
Assign inside by 50-100 mg 1 time / day.
Thrombo ACC® is for long-term use. The duration of therapy is determined individually.
Side effects
Allergic reactions: urticaria, Quincke's edema, anaphylactic reactions.
From the digestive system: nausea, heartburn, vomiting, abdominal pain, ulcers of the mucous membrane of the stomach and duodenum (including perforated), increased activity of liver enzymes.
From the respiratory system: bronchospasm.
From the hemopoietic system: anemia (rarely), increased bleeding.
From the side of the central nervous system: dizziness, tinnitus.
In general, thrombo ACC® is well tolerated by patients (due to the low content of acetylsalicylic acid in the preparation). Side effects are noted in individual cases.
Drug Interactions
With the simultaneous use of Thrombo ACC®, it enhances the action of the following drugs: - methotrexate by reducing renal clearance and displacing it from
proteins - heparin and indirect anticoagulants due to impaired platelet function and anti-agglomeration
- thrombolytic and antiplatelet agents (ticlopidine)
- digoxin due to a decrease in its renal excretion
- hypoglycemic agents (insulin, etc. sulfonylurea derivatives) due to the hypoglycemic properties of the ASA in high doses and displacement of sulfonylurea derivatives linkages with proteins
- valproic acid due to displacement from its bonds with proteins.
An additive effect is observed while taking ASA with ethanol.
ASA weakens the action of uricosuric agents (benzbromarone) due to competitive tubular elimination of uric acid.
With the simultaneous use of GCS, they enhance the excretion of salicylates and weaken their effect.
Overdose
An overdose is unlikely due to the low ASA content of the drug. Excess dose of ASA is associated with the risk of gastrointestinal bleeding. Overdose is especially dangerous in elderly patients.
Symptoms: nausea, vomiting, tinnitus, dizziness, confusion, general malaise.
Treatment: artificial vomiting, the appointment of activated carbon, laxatives, if necessary, correct the acid-base balance.
Storage conditions
The product should be stored in a dry, dark place out of the reach of children at a temperature not exceeding 25 РC.
Shelf life
3 years.
Deystvuyushtee substance
Atsetilsalitsilovaya Chisloth
Terms and conditions otpuska IZ
pharmacies without a prescription
dosage form
tablets
Indications
Indications
Pros lactation of thromboembolism, Prevention of stroke, Prevention of thrombosis, Angina pectoris, Prevention of acute myocardial infarction
G.L. Pharma GmbH, A Istria
Enteric coated tablets.
Packing
100 pcs.
Pharmacological action
Thrombo Ass - NSAIDs, antiplatelet agent.
Reduces blood coagulation due to a decrease in platelet aggregation by suppressing the synthesis of thromboxane A2 in them.
The use of thrombo ACC, starting with a dose of 50 mg, leads to a long-term decrease of serum thromboxane A2 and its metabolites by 90-95%.
It also has anti-inflammatory, analgesic and antipyretic effects.
The tablets of the drug are coated with a film of enteric coat resistant to the action of gastric juice, which reduces the risk of side effects from the stomach.
Indications
- prevention of acute myocardial infarction in the presence of risk factors (such as diabetes mellitus, hyperlipidemia, hypertension, obesity, smoking, elderly)
- secondary prevention of myocardial infarction
- unstable angina pectoris (
- angina pectoris in patients with transient cerebrovascular diseases)
- prevention of transient cerebrovascular disorders
- prevention of thromboembolism after surgery and invasive vascular interventions (such ak aorto-coronary bypass, carotid endarterectomy, arterio-venous bypass, angioplasty, carotid arteries)
- prevention of deep vein thrombosis and pulmonary artery and its branches (e.g., with prolonged immobilization as a result of serious surgery).
Contraindications
- erosive and ulcerative lesions of the gastrointestinal tract, gastrointestinal bleeding
- aspirin asthma (bronchial asthma induced by taking salicylates and NSAIDs)
- aspirin triad (a combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and intolerance to acetylsalicylic acid)
- hemorrhagic diathesis
- combined use with methotrexate at a dose of 15 mg or more per week
- I and III trimesters of pregnancy
- lactation (breastfeeding and nursing) 18 years of
- hypersensitivity to acetylsalicylic acid, to excipients of the drug Thrombo ACC and other NSAIDs.
It is prescribed with caution in case of gout, hyperuricemia, gastrointestinal ulcer or history of gastrointestinal bleeding, renal and hepatic insufficiency, bronchial asthma, chronic respiratory diseases, hay fever, nasal polyposis, allergic reactions to medications, history with simultaneous use with methotrexate at a dose of 15 mg or less per week.
Use during pregnancy and lactation
The use of high doses of salicylates in the first 3 months of pregnancy is associated with an increased incidence of fetal developmental defects (split palate, heart defects). In the second trimester of pregnancy, salicylates can only be prescribed with a strict assessment of risk and benefit. The appointment of ASA in the last trimester is contraindicated.
Salicylates and their metabolites in small doses pass into breast milk. Long-term use of salicylates is a reason for stopping breastfeeding. A random intake of salicylates during lactation is not accompanied by the development of adverse reactions in the child and does not require cessation of breastfeeding.
Special instructions
ASA can cause bronchospasm, as well as cause asthma attacks and other hypersensitivity reactions. Risk factors are a history of asthma, hay fever, nasal polyposis, chronic respiratory diseases, as well as allergic reactions to other drugs (itching, urticaria).
ASA can cause bleeding of varying severity during and after surgery.
The combination of ASA with anticoagulants, thrombolytics, antiplatelet agents is associated with an increased risk of bleeding.
ASA in low doses can trigger gout in susceptible individuals with decreased uric acid excretion.
The combination of ASA with methotrexate is accompanied by an increased incidence of side effects from the hematopoietic system.
High doses of ASA have a hypoglycemic effect, which must be considered when prescribing it to patients with diabetes mellitus receiving hypoglycemic drugs.
When combined with GCS, it should be remembered that during treatment, the level of salicylates in the blood is reduced, and after the abolition of GCS, an overdose of salicylates is possible.
The combination of ASA with ibuprofen is not recommended, since the latter worsens the beneficial effect of ASA on life expectancy.
When combined with ASA and alcohol, the risk of damage to the gastrointestinal mucosa and prolonged bleeding time is increased.
Composition
1 tablet: - acetylsalicylic acid 50 mg.
Excipients:
lactose, microcrystalline cellulose,
silicon dioxide colloidal,
potato starch,
talcum powder,
triacetin,
silicone anti-foaming agent SE2,
is emulsified with L30D (methacrylic acid and ethacrylate copolymer).
Dosage and Administration
Thrombo ACC tablets should be taken orally without chewing before meals with a small amount of liquid.
Assign inside by 50-100 mg 1 time / day.
Thrombo ACC® is for long-term use. The duration of therapy is determined individually.
Side effects
Allergic reactions: urticaria, Quincke's edema, anaphylactic reactions.
From the digestive system: nausea, heartburn, vomiting, abdominal pain, ulcers of the mucous membrane of the stomach and duodenum (including perforated), increased activity of liver enzymes.
From the respiratory system: bronchospasm.
From the hemopoietic system: anemia (rarely), increased bleeding.
From the side of the central nervous system: dizziness, tinnitus.
In general, thrombo ACC® is well tolerated by patients (due to the low content of acetylsalicylic acid in the preparation). Side effects are noted in individual cases.
Drug Interactions
With the simultaneous use of Thrombo ACC®, it enhances the action of the following drugs: - methotrexate by reducing renal clearance and displacing it from
proteins - heparin and indirect anticoagulants due to impaired platelet function and anti-agglomeration
- thrombolytic and antiplatelet agents (ticlopidine)
- digoxin due to a decrease in its renal excretion
- hypoglycemic agents (insulin, etc. sulfonylurea derivatives) due to the hypoglycemic properties of the ASA in high doses and displacement of sulfonylurea derivatives linkages with proteins
- valproic acid due to displacement from its bonds with proteins.
An additive effect is observed while taking ASA with ethanol.
ASA weakens the action of uricosuric agents (benzbromarone) due to competitive tubular elimination of uric acid.
With the simultaneous use of GCS, they enhance the excretion of salicylates and weaken their effect.
Overdose
An overdose is unlikely due to the low ASA content of the drug. Excess dose of ASA is associated with the risk of gastrointestinal bleeding. Overdose is especially dangerous in elderly patients.
Symptoms: nausea, vomiting, tinnitus, dizziness, confusion, general malaise.
Treatment: artificial vomiting, the appointment of activated carbon, laxatives, if necessary, correct the acid-base balance.
Storage conditions
The product should be stored in a dry, dark place out of the reach of children at a temperature not exceeding 25 РC.
Shelf life
3 years.
Deystvuyushtee substance
Atsetilsalitsilovaya Chisloth
Terms and conditions otpuska IZ
pharmacies without a prescription
dosage form
tablets
Indications
Indications
Pros lactation of thromboembolism, Prevention of stroke, Prevention of thrombosis, Angina pectoris, Prevention of acute myocardial infarction
G.L. Pharma GmbH, A Istria
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review